OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades
Elias Jabbour, Nicholas J. Short, Nitin Jain, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 60
Elias Jabbour, Nicholas J. Short, Nitin Jain, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 60
Showing 1-25 of 60 citing articles:
Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia
Elias Jabbour, Gerhard Zugmaier, Vaibhav Agrawal, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 4, pp. 586-595
Open Access | Times Cited: 21
Elias Jabbour, Gerhard Zugmaier, Vaibhav Agrawal, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 4, pp. 586-595
Open Access | Times Cited: 21
The application of Aptamer in biomarker discovery
Yongshu Li, Winnie W. L. Tam, Yuanyuan Yu, et al.
Biomarker Research (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 33
Yongshu Li, Winnie W. L. Tam, Yuanyuan Yu, et al.
Biomarker Research (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 33
Advances in molecular targeted drugs in combination with CAR-T cell therapy for hematologic malignancies
Yuxian Huang, Yinjie Qin, Yingzhi He, et al.
Drug Resistance Updates (2024) Vol. 74, pp. 101082-101082
Open Access | Times Cited: 11
Yuxian Huang, Yinjie Qin, Yingzhi He, et al.
Drug Resistance Updates (2024) Vol. 74, pp. 101082-101082
Open Access | Times Cited: 11
Galectin-9 in cancer therapy: from immune checkpoint ligand to promising therapeutic target
Minpu Zhang, Cun Liu, Li Ye, et al.
Frontiers in Cell and Developmental Biology (2024) Vol. 11
Open Access | Times Cited: 10
Minpu Zhang, Cun Liu, Li Ye, et al.
Frontiers in Cell and Developmental Biology (2024) Vol. 11
Open Access | Times Cited: 10
Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22+ acute lymphoblastic leukemia: results of the phase IB ITCC-059 trial
Edoardo Pennesi, Erica Brivio, Anneke C. J. Ammerlaan, et al.
Haematologica (2024) Vol. 109, Iss. 10, pp. 3157-3166
Open Access | Times Cited: 7
Edoardo Pennesi, Erica Brivio, Anneke C. J. Ammerlaan, et al.
Haematologica (2024) Vol. 109, Iss. 10, pp. 3157-3166
Open Access | Times Cited: 7
B-Cell Receptor Repertoire: Recent Advances in Autoimmune Diseases
Qian Wang, Delong Feng, Sujie Jia, et al.
Clinical Reviews in Allergy & Immunology (2024) Vol. 66, Iss. 1, pp. 76-98
Closed Access | Times Cited: 6
Qian Wang, Delong Feng, Sujie Jia, et al.
Clinical Reviews in Allergy & Immunology (2024) Vol. 66, Iss. 1, pp. 76-98
Closed Access | Times Cited: 6
Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions
Nicholas J. Short, Elias Jabbour, Nitin B. Jain, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 6
Nicholas J. Short, Elias Jabbour, Nitin B. Jain, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 6
Naked antibodies and antibody-drug conjugates: targeted therapy for childhood acute lymphoblastic leukemia
Erica Brivio, Francisco Bautista, C. Michel Zwaan
Haematologica (2024) Vol. 109, Iss. 6, pp. 1700-1712
Open Access | Times Cited: 6
Erica Brivio, Francisco Bautista, C. Michel Zwaan
Haematologica (2024) Vol. 109, Iss. 6, pp. 1700-1712
Open Access | Times Cited: 6
SOHO State of the Art Updates and Next Questions | Next Questions: Acute Lymphoblastic Leukemia
Jayastu Senapati, Hagop M. Kantarjian, Fadi G. Haddad, et al.
Clinical Lymphoma Myeloma & Leukemia (2024) Vol. 24, Iss. 6, pp. 333-339
Closed Access | Times Cited: 5
Jayastu Senapati, Hagop M. Kantarjian, Fadi G. Haddad, et al.
Clinical Lymphoma Myeloma & Leukemia (2024) Vol. 24, Iss. 6, pp. 333-339
Closed Access | Times Cited: 5
Pediatric-inspired regimen for adolescent and adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: a prospective study from China
Xiaoyuan Gong, Qiuyun Fang, Runxia Gu, et al.
Haematologica (2024) Vol. 109, Iss. 10, pp. 3146-3156
Open Access | Times Cited: 5
Xiaoyuan Gong, Qiuyun Fang, Runxia Gu, et al.
Haematologica (2024) Vol. 109, Iss. 10, pp. 3146-3156
Open Access | Times Cited: 5
The Evolving Landscape of Flowcytometric Minimal Residual Disease Monitoring in B-Cell Precursor Acute Lymphoblastic Leukemia
Martijn W. C. Verbeek, Vincent H. J. van der Velden
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 9, pp. 4881-4881
Open Access | Times Cited: 5
Martijn W. C. Verbeek, Vincent H. J. van der Velden
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 9, pp. 4881-4881
Open Access | Times Cited: 5
Ponatinib‐review of historical development, current status, and future research
Hagop M. Kantarjian, Helen T. Chifotides, Fadi G. Haddad, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 8, pp. 1576-1585
Closed Access | Times Cited: 5
Hagop M. Kantarjian, Helen T. Chifotides, Fadi G. Haddad, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 8, pp. 1576-1585
Closed Access | Times Cited: 5
Bcl-2 family inhibitors sensitize human cancer models to therapy
Elisabetta Valentini, Marta Di Martile, Matteo Brignone, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 7
Open Access | Times Cited: 14
Elisabetta Valentini, Marta Di Martile, Matteo Brignone, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 7
Open Access | Times Cited: 14
Diagnostic and therapeutic advances in adults with acute lymphoblastic leukemia in the era of gene analysis and targeted immunotherapy
Jae‐Ho Yoon, Seok Lee
The Korean Journal of Internal Medicine (2024) Vol. 39, Iss. 1, pp. 34-56
Open Access | Times Cited: 4
Jae‐Ho Yoon, Seok Lee
The Korean Journal of Internal Medicine (2024) Vol. 39, Iss. 1, pp. 34-56
Open Access | Times Cited: 4
Evaluation of Ferroptosis-Based Anti-Leukemic Activities of ZnO Nanoparticles Synthesized by a Green Route Against Pre-B Acute Lymphoblastic Leukemia Cells (Nalm-6 and REH)
Muhammad Hossein Ashoub, Mahnaz Amiri, Ahmad Fatemi, et al.
Heliyon (2024) Vol. 10, Iss. 17, pp. e36608-e36608
Closed Access | Times Cited: 4
Muhammad Hossein Ashoub, Mahnaz Amiri, Ahmad Fatemi, et al.
Heliyon (2024) Vol. 10, Iss. 17, pp. e36608-e36608
Closed Access | Times Cited: 4
Inotuzumab Ozogamicin as First-Line Therapy in Acute Lymphoblastic Leukemia
Elias Jabbour, Philippe Rousselot, Nicola Gökbuget, et al.
Clinical Lymphoma Myeloma & Leukemia (2025)
Closed Access
Elias Jabbour, Philippe Rousselot, Nicola Gökbuget, et al.
Clinical Lymphoma Myeloma & Leukemia (2025)
Closed Access
How to use monoclonal antibody-based therapy in ALL
Erica Brivio, Sujith Samarasinghe
EJC Paediatric Oncology (2025), pp. 100214-100214
Open Access
Erica Brivio, Sujith Samarasinghe
EJC Paediatric Oncology (2025), pp. 100214-100214
Open Access
Frontline immunotherapeutic combination strategies in adult B-cell acute lymphoblastic leukemia: reducing chemotherapy intensity and toxicity and harnessing efficacy
Jayastu Senapati, Hagop M. Kantarjian, Diane Habib, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2025), pp. 1-12
Closed Access
Jayastu Senapati, Hagop M. Kantarjian, Diane Habib, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2025), pp. 1-12
Closed Access
Avances en inmunoterapia para leucemia linfocítica aguda: integración de terapias con células car-T y otras estrategias inmunológicas
Vladimir Moreta, Daniela Alexandra Rosero Freire
Bionatura journal : (2025) Vol. 2, Iss. 1, pp. 1-23
Closed Access
Vladimir Moreta, Daniela Alexandra Rosero Freire
Bionatura journal : (2025) Vol. 2, Iss. 1, pp. 1-23
Closed Access
The impact of obesity and its related underlying diseases on cytokine release syndrome and the efficacy of CAR-T therapy in treating B-cell malignancies
Mengyi Du, Rosanna Tryphene Massounga Mayombo, Jiachen Liu, et al.
Research Square (Research Square) (2025)
Closed Access
Mengyi Du, Rosanna Tryphene Massounga Mayombo, Jiachen Liu, et al.
Research Square (Research Square) (2025)
Closed Access
Acute Lymphoid Leukaemia and Minimal/Measurable Residual Disease
Barbara Buldini, Elena Varotto, Andrea Zangrando
Cambridge University Press eBooks (2025), pp. 93-107
Closed Access
Barbara Buldini, Elena Varotto, Andrea Zangrando
Cambridge University Press eBooks (2025), pp. 93-107
Closed Access
Efficacy and safety of CAR-T cell therapy in B-ALL patients previously treated with blinatumomab
Yurou Chu, Biqi Zhou, Rui Gao, et al.
Blood Cancer Journal (2025) Vol. 15, Iss. 1
Open Access
Yurou Chu, Biqi Zhou, Rui Gao, et al.
Blood Cancer Journal (2025) Vol. 15, Iss. 1
Open Access
Therapeutic Strategies for Relapsed or Refractory B‐Cell Acute Lymphoblastic Leukemia in Adult Patients: Optimizing the Use of Monoclonal Antibodies
Antonella Bruzzese, Enrica Antonia Martino, Caterina Labanca, et al.
European Journal Of Haematology (2025)
Open Access
Antonella Bruzzese, Enrica Antonia Martino, Caterina Labanca, et al.
European Journal Of Haematology (2025)
Open Access
BASP1 is a potential relapse-associated diagnostic marker for adult patients with B-cell acute lymphoblastic leukemia
Haiyu Song, Ruiqi Wang, Weijie Liao, et al.
Genome Instability & Disease (2025)
Closed Access
Haiyu Song, Ruiqi Wang, Weijie Liao, et al.
Genome Instability & Disease (2025)
Closed Access
Quality‐Adjusted Time Without Symptoms of Disease or Toxicity (Q‐TWiST ) in Patients With Newly Diagnosed Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia: A Comparison of Ponatinib Versus Imatinib
Ajibade Ashaye, Ling Shi, Ibrahim Aldoss, et al.
Cancer Medicine (2025) Vol. 14, Iss. 7
Open Access
Ajibade Ashaye, Ling Shi, Ibrahim Aldoss, et al.
Cancer Medicine (2025) Vol. 14, Iss. 7
Open Access
